BIOVENTUS INC - A (BVS) Stock Fundamental Analysis
NASDAQ:BVS - Nasdaq - US09075A1088 - Common Stock - Currency: USD
Taking everything into account, BVS scores 3 out of 10 in our fundamental rating. BVS was compared to 190 industry peers in the Health Care Equipment & Supplies industry. While BVS is still in line with the averages on profitability rating, there are concerns on its financial health. BVS has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
BVS had positive earnings in the past year.
In the past year BVS had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: BVS reported negative net income in multiple years.
BVS had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
The Return On Assets of BVS (-5.13%) is better than 64.36% of its industry peers.
BVS has a Return On Equity (-26.54%) which is comparable to the rest of the industry.
With a decent Return On Invested Capital value of 2.30%, BVS is doing good in the industry, outperforming 71.28% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -5.13% | ||
| ROE | -26.54% | ||
| ROIC | 2.3% |
ROA(3y)-9.75%
ROA(5y)-5.7%
ROE(3y)-45.3%
ROE(5y)-26.66%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Operating Margin, with a value of 2.92%, BVS is in the better half of the industry, outperforming 68.09% of the companies in the same industry.
BVS's Operating Margin has declined in the last couple of years.
BVS has a better Gross Margin (67.00%) than 72.34% of its industry peers.
In the last couple of years the Gross Margin of BVS has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 2.92% | ||
| PM (TTM) | N/A | ||
| GM | 67% |
OM growth 3Y-68.96%
OM growth 5Y-50.5%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.13%
GM growth 5Y-2.74%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so BVS is destroying value.
Compared to 1 year ago, BVS has more shares outstanding
BVS has more shares outstanding than it did 5 years ago.
The debt/assets ratio for BVS is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of 1.06, we must say that BVS is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.06, BVS is in line with its industry, outperforming 51.06% of the companies in the same industry.
The Debt to FCF ratio of BVS is 13.21, which is on the high side as it means it would take BVS, 13.21 years of fcf income to pay off all of its debts.
With a decent Debt to FCF ratio value of 13.21, BVS is doing good in the industry, outperforming 71.28% of the companies in the same industry.
A Debt/Equity ratio of 2.32 is on the high side and indicates that BVS has dependencies on debt financing.
BVS has a worse Debt to Equity ratio (2.32) than 85.11% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.32 | ||
| Debt/FCF | 13.21 | ||
| Altman-Z | 1.06 |
ROIC/WACC0.25
WACC9.17%
2.3 Liquidity
BVS has a Current Ratio of 1.41. This is a normal value and indicates that BVS is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.41, BVS is not doing good in the industry: 79.26% of the companies in the same industry are doing better.
BVS has a Quick Ratio of 1.41. This is a bad value and indicates that BVS is not financially healthy enough and could expect problems in meeting its short term obligations.
BVS has a worse Quick ratio (0.99) than 79.26% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.41 | ||
| Quick Ratio | 0.99 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 400.00% over the past year.
The Revenue has grown by 10.39% in the past year. This is quite good.
BVS shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 9.93% yearly.
EPS 1Y (TTM)400%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20%
Revenue 1Y (TTM)10.39%
Revenue growth 3Y16.84%
Revenue growth 5Y9.93%
Sales Q2Q%15.04%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
The Revenue is expected to grow by 5.69% on average over the next years.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year12.78%
Revenue Next 2Y5.23%
Revenue Next 3Y5.69%
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 25.67, BVS can be considered very expensive at the moment.
Based on the Price/Earnings ratio, BVS is valued cheaply inside the industry as 80.32% of the companies are valued more expensively.
BVS is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 29.63, which is the current average of the S&P500 Index.
With a Price/Forward Earnings ratio of 18.02, BVS is valued on the expensive side.
Based on the Price/Forward Earnings ratio, BVS is valued cheaply inside the industry as 85.11% of the companies are valued more expensively.
BVS's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 22.68.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.67 | ||
| Fwd PE | 18.02 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, BVS is valued cheaper than 80.32% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, BVS is valued cheaper than 84.04% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 27.97 | ||
| EV/EBITDA | 17.44 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
BVS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
10.01
+0.06 (+0.6%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners70.7%
Inst Owner Change2%
Ins Owners2.11%
Ins Owner Change1.39%
Market Cap812.31M
Analysts77.14
Price Target15.3 (52.85%)
Short Float %1.41%
Short Ratio2.98
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)140.09%
Min EPS beat(2)98.02%
Max EPS beat(2)182.16%
EPS beat(4)4
Avg EPS beat(4)179.78%
Min EPS beat(4)98.02%
Max EPS beat(4)246.54%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)6.04%
Min Revenue beat(2)3.27%
Max Revenue beat(2)8.81%
Revenue beat(4)4
Avg Revenue beat(4)7.13%
Min Revenue beat(4)3.27%
Max Revenue beat(4)8.81%
Revenue beat(8)7
Avg Revenue beat(8)3.63%
Revenue beat(12)8
Avg Revenue beat(12)1.43%
Revenue beat(16)11
Avg Revenue beat(16)2.23%
PT rev (1m)0%
PT rev (3m)3.45%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-0.82%
EPS NY rev (3m)-0.82%
Revenue NQ rev (1m)0.23%
Revenue NQ rev (3m)0.23%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.12%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.67 | ||
| Fwd PE | 18.02 | ||
| P/S | 1.46 | ||
| P/FCF | 27.97 | ||
| P/OCF | 27.22 | ||
| P/B | 5.46 | ||
| P/tB | N/A | ||
| EV/EBITDA | 17.44 |
EPS(TTM)0.39
EY3.9%
EPS(NY)0.56
Fwd EY5.55%
FCF(TTM)0.36
FCFY3.58%
OCF(TTM)0.37
OCFY3.67%
SpS6.84
BVpS1.83
TBVpS-3.37
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -5.13% | ||
| ROE | -26.54% | ||
| ROCE | 2.91% | ||
| ROIC | 2.3% | ||
| ROICexc | 2.49% | ||
| ROICexgc | 13.83% | ||
| OM | 2.92% | ||
| PM (TTM) | N/A | ||
| GM | 67% | ||
| FCFM | 5.23% |
ROA(3y)-9.75%
ROA(5y)-5.7%
ROE(3y)-45.3%
ROE(5y)-26.66%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y-73.25%
ROICexcg growth 5Y-53.85%
ROICexc growth 3Y-71.68%
ROICexc growth 5Y-51.56%
OM growth 3Y-68.96%
OM growth 5Y-50.5%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.13%
GM growth 5Y-2.74%
F-Score6
Asset Turnover0.72
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.32 | ||
| Debt/FCF | 13.21 | ||
| Debt/EBITDA | 5.24 | ||
| Cap/Depr | 1.62% | ||
| Cap/Sales | 0.14% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 45.33% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.41 | ||
| Quick Ratio | 0.99 | ||
| Altman-Z | 1.06 |
F-Score6
WACC9.17%
ROIC/WACC0.25
Cap/Depr(3y)16.33%
Cap/Depr(5y)14.2%
Cap/Sales(3y)1.7%
Cap/Sales(5y)1.41%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)400%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)10.39%
Revenue growth 3Y16.84%
Revenue growth 5Y9.93%
Sales Q2Q%15.04%
Revenue Next Year12.78%
Revenue Next 2Y5.23%
Revenue Next 3Y5.69%
Revenue Next 5YN/A
EBIT growth 1Y174.42%
EBIT growth 3Y-63.73%
EBIT growth 5Y-45.59%
EBIT Next Year155.56%
EBIT Next 3Y43.57%
EBIT Next 5YN/A
FCF growth 1Y292.34%
FCF growth 3Y-50.97%
FCF growth 5Y-28.47%
OCF growth 1Y627.33%
OCF growth 3Y-40.21%
OCF growth 5Y-19.43%